重组人粒细胞刺激因子对肿瘤化疗后骨髓抑制作用分析
|
摘要
目的探讨不同骨髓抑制时期应用重组人粒细胞刺激因子对化疗后白细胞和中性粒细胞减少的防治作用.方法回顾性分析200例化疗后出现骨髓抑制且应用重组人粒细胞刺激因子的恶性肿瘤患者资料,通过对患者用药前后血常规的检查,观察恢复天数和用药前后白细胞和中性粒细胞计数的变化,比较不同骨髓抑制时期给药后患者的恢复程度,以此评估疗效.结果治疗后患者白细胞和中性粒细胞计数有显著升高,恢复正常值平均需要2.72 d,药物的有效率为96.50%,其中Ⅱ度骨髓抑制患者治愈率可达到100%.结论重组人粒细胞刺激因子对骨髓抑制的疗效明显,不良反应小,安全性高,最佳给药时机为Ⅱ度骨髓抑制时期.
Objective To investigate the preventive and therapeutic effects of recombinant human granulocyte stimulating factor( rhGMF) on leukopenia and neutropenia after chemotherapy in different myelosuppressive stages.Method A retrospective analysis was made on 200 cases of malignant tumors with myelosuppression after chemotherapy and recombinant human granulocyte stimulating factor( rh GMF). The changes of leukocyte and neutrophil counts before and after treatment were observed by routine blood tests before and after treatment,and the degree of recovery after treatment was compared in different periods of myelosuppression in order to evaluate the curative effect. Results The neutrophil count increased significantly after treatment. The cure rate of the patients with grade II myelosuppression was 100%.The average time for neutrophil to return to normal was 2.72 days.The effective rate of rhG-CSF was 96.50%.Conclusion The curative effect on bone marrow depression has little adverse reaction and high safety. The best time of administration is the second degree bone marrow depression.
Objective To investigate the preventive and therapeutic effects of recombinant human granulocyte stimulating factor( rhGMF) on leukopenia and neutropenia after chemotherapy in different myelosuppressive stages.Method A retrospective analysis was made on 200 cases of malignant tumors with myelosuppression after chemotherapy and recombinant human granulocyte stimulating factor( rh GMF). The changes of leukocyte and neutrophil counts before and after treatment were observed by routine blood tests before and after treatment,and the degree of recovery after treatment was compared in different periods of myelosuppression in order to evaluate the curative effect. Results The neutrophil count increased significantly after treatment. The cure rate of the patients with grade II myelosuppression was 100%.The average time for neutrophil to return to normal was 2.72 days.The effective rate of rhG-CSF was 96.50%.Conclusion The curative effect on bone marrow depression has little adverse reaction and high safety. The best time of administration is the second degree bone marrow depression.
引文
[1] Amdt C A,Koshkina N V,Inwards C Y,et al. Inhaledgranulocy-temacrohage colony stimulating factor for firstpulmonary recurrence of osteosarcoma:effects on disease-free survival and immunomo-dulation a report from thechildren’s oncology group[J].Clin Cancer Res,2010,16(15):4024-4030.
[2]林万龙,陈瑶,杨剑辉.重组人粒细胞刺激因子用于乳腺癌化疗后辅助治疗专项点评[J].中国现代应用药学,2018,35(6):900-904.
[3]周弦.探究聚乙二醇化重组人粒细胞集落刺激因子对化疗相关性粒细胞减少骨髓抑制的预防效果[J].川北医学院学报,2018,33(2):213-216.
[4]夏修远,房文铮,宋洪涛.重组人粒细胞集落刺激因子预防肿瘤化疗后骨髓抑制的疗效分析[J].中南药学,2012,10(3):229-232.
[5]张宇峰,付培婷,刘秀宝,等.当归补血汤联合重组人粒细胞刺激因子防治乳腺癌化疗后骨髓抑制效果观察[J].临床合理用药,2015,8(10):8-10.
[6]赵利红,汪海岩.晚期肺癌化疗后重组人粒细胞刺激因子对骨髓抑制的临床疗效[J].中国老年学杂志,2011,31(12):4559~4560.
[7] Ozer H,Armitage J O,Bennett C L,et al.2000 update ofrecommendations for the use of hematopoietic colony-stimulating factors:evidence-based, clinical practiceguidelines[J].J Clin Oncol,2000,18(20):3558-3585.
[8]宋春影.重组人粒细胞刺激因子治疗化疗所致骨髓抑制的疗效观察[J].按摩与康复医学,2011,48(4):135.
[9]雷双根.重组人粒细胞集落刺激因子治疗乳腺癌术后化疗后骨髓抑制的疗效[J].实用临床医学,2014,15(7):28-30.
[10]张力,李龙芸,林宏英,等.重组人粒细胞集落刺激因子对肿瘤患者白细胞的影响[J].中国临床药学杂志,2001,10(4):207-210.
[11] Wingard J R,Elmongy M.Strategies for minimizing compl-ications of neutropenia:prophylactic myeloid growth factorsor antibiotics[J]. Crit Rev Oncol Hematol,2009,72(2):54-144.
[2]林万龙,陈瑶,杨剑辉.重组人粒细胞刺激因子用于乳腺癌化疗后辅助治疗专项点评[J].中国现代应用药学,2018,35(6):900-904.
[3]周弦.探究聚乙二醇化重组人粒细胞集落刺激因子对化疗相关性粒细胞减少骨髓抑制的预防效果[J].川北医学院学报,2018,33(2):213-216.
[4]夏修远,房文铮,宋洪涛.重组人粒细胞集落刺激因子预防肿瘤化疗后骨髓抑制的疗效分析[J].中南药学,2012,10(3):229-232.
[5]张宇峰,付培婷,刘秀宝,等.当归补血汤联合重组人粒细胞刺激因子防治乳腺癌化疗后骨髓抑制效果观察[J].临床合理用药,2015,8(10):8-10.
[6]赵利红,汪海岩.晚期肺癌化疗后重组人粒细胞刺激因子对骨髓抑制的临床疗效[J].中国老年学杂志,2011,31(12):4559~4560.
[7] Ozer H,Armitage J O,Bennett C L,et al.2000 update ofrecommendations for the use of hematopoietic colony-stimulating factors:evidence-based, clinical practiceguidelines[J].J Clin Oncol,2000,18(20):3558-3585.
[8]宋春影.重组人粒细胞刺激因子治疗化疗所致骨髓抑制的疗效观察[J].按摩与康复医学,2011,48(4):135.
[9]雷双根.重组人粒细胞集落刺激因子治疗乳腺癌术后化疗后骨髓抑制的疗效[J].实用临床医学,2014,15(7):28-30.
[10]张力,李龙芸,林宏英,等.重组人粒细胞集落刺激因子对肿瘤患者白细胞的影响[J].中国临床药学杂志,2001,10(4):207-210.
[11] Wingard J R,Elmongy M.Strategies for minimizing compl-ications of neutropenia:prophylactic myeloid growth factorsor antibiotics[J]. Crit Rev Oncol Hematol,2009,72(2):54-144.